达雷妥尤单抗使用与美国成人病例系列中眼部事件的关联。
Association of Daratumumab Use With Ocular Events in a Case Series of US Adults.
机构信息
Division of Pharmacovigilance, Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland.
Division of Ophthalmology, Office of Specialty Medicine, US Food and Drug Administration, Silver Spring, Maryland.
出版信息
JAMA Oncol. 2022 Aug 1;8(8):1209-1210. doi: 10.1001/jamaoncol.2022.1634.
Abstract
This case series uses postmarketing data to evaluate the association of daratumumab use with ocular events such as acute angle-closure glaucoma, myopic shift, and choroidal effusions among US adults.
摘要
本病例系列研究使用上市后数据评估了达雷妥尤单抗在美国成年人中的应用与眼部事件（如急性闭角型青光眼、近视漂移和脉络膜积液）之间的关联。
相似文献
1
Association of Daratumumab Use With Ocular Events in a Case Series of US Adults.达雷妥尤单抗使用与美国成人病例系列中眼部事件的关联。
JAMA Oncol. 2022 Aug 1;8(8):1209-1210. doi: 10.1001/jamaoncol.2022.1634.
2
Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma.卡非佐米联合达雷妥尤单抗治疗多发性骨髓瘤复发。
Future Oncol. 2021 Mar;17(9):993-998. doi: 10.2217/fon-2020-0907. Epub 2020 Dec 8.
3
Use of Daratumumab in Patients With Previously Treated Multiple Myeloma.达雷妥尤单抗在既往接受过治疗的多发性骨髓瘤患者中的应用。
J Clin Oncol. 2023 May 10;41(14):2668. doi: 10.1200/JCO.22.02850. Epub 2023 Mar 20.
4
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.达雷妥尤单抗联合来那度胺和地塞米松治疗复发或复发/难治性多发性骨髓瘤患者的持久疗效和耐受性（GEN503）：一项开放标签的1/2期研究的最终结果
Br J Haematol. 2019 Aug;186(3):e35-e39. doi: 10.1111/bjh.15879. Epub 2019 Mar 31.
5
Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma.达雷妥尤单抗治疗多发性骨髓瘤患者时出现的早期白质脑病。
Ann Hematol. 2023 Apr;102(4):967-969. doi: 10.1007/s00277-023-05120-w. Epub 2023 Feb 8.
6
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.达雷妥尤单抗、来那度胺和地塞米松与来那度胺和地塞米松单独治疗新诊断多发性骨髓瘤（MAIA）的疗效比较：一项随机、开放标签、3 期临床试验的总生存结果。
Lancet Oncol. 2021 Nov;22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6. Epub 2021 Oct 13.
7
[New European approvals: Carfilzomib with daratumumab and dexamethasone in refractory or relapsed multiple myeloma after a first line of treatment].[欧洲新获批药物：卡非佐米联合达雷妥尤单抗及地塞米松用于一线治疗后难治性或复发性多发性骨髓瘤]
Bull Cancer. 2021 Jun;108(6):563-565. doi: 10.1016/j.bulcan.2021.04.005. Epub 2021 May 19.
8
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
9
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.达雷妥尤单抗联合泊马度胺和地塞米松与泊马度胺和地塞米松单药治疗既往治疗的多发性骨髓瘤（APOLLO）：一项开放标签、随机、III 期临床试验。
Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5.
10
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.达雷妥尤单抗、来那度胺和地塞米松用于复发多发性骨髓瘤的1/2期研究。
Blood. 2016 Oct 6;128(14):1821-1828. doi: 10.1182/blood-2016-07-726729. Epub 2016 Aug 16.
引用本文的文献
1
CD38-NAD(+) Axis: New Insights into Glaucoma Therapy.CD38 - NAD(+)轴：青光眼治疗的新见解
Mol Neurobiol. 2025 Jul 22. doi: 10.1007/s12035-025-05243-3.
Zotero 插件